Evaluating Aripiprazole and Sensorimotor Speech Processing in Adults Who Stutter
Led by University of California, San Francisco · Updated on 2026-08-19
25
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of aripiprazole on adults who stutter, a condition that affects speech fluency and impacts millions. The study aims to understand how dopamine regulation and auditory feedback changes influence sensorimotor speech pathways. This research could support future combined treatments involving dopamine regulators and behavioral approaches.
Participants will receive either a single 10 mg oral dose of aripiprazole or a placebo in a randomized, crossover design with triple masking. The study investigates how these treatments affect speech fluency and neural responses related to auditory feedback and sensorimotor function.
During the study, participants undergo assessments 3 to 4 hours after dosing, including measurements of pre-speech auditory modulation, speaking induced suppression, centering, and feedback alterations. The study involves healthy adult participants aged 18 to 65 years who are native American English speakers and have confirmed stuttering since childhood.
CONDITIONS
Brief Title
Dopamine and Sensorimotor Function in Stuttering
Research Team
N
Natalie Brunwin, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Aripiprazole 10 mg single dose
Placebo single dose
What it is
A single oral dose of aripiprazole, an antipsychotic drug that modulates dopamine activity, administered as part of an experimental protocol.
A single oral dose of placebo designed to mimic the active drug for participant blinding and comparison.
Role in trial
Investigational condition assessed for effects on speech, behavioral, and neural outcomes in adults who stutter.
Control condition allowing investigators to compare outcomes with and without active drug exposure.
Primary use
Studied for its potential to affect stuttering and related sensorimotor and neural markers in adults.
Serves as a standard of comparison to assess whether changes are due to aripiprazole rather than expectation or normal fluctuation.
How it is given or performed
A single oral tablet of aripiprazole 10 mg, given during one study session.
A single oral placebo tablet, given in a matched session to the active drug period.
Evidence status
The effectiveness of aripiprazole for stuttering remains under investigation, with limited published studies to date.
Placebo is not intended to directly improve stuttering and serves as a physiologic control in research settings.
Important limitations
Evidence for the effects of aripiprazole on stuttering is limited, with most research involving small samples or case reports.
As placebo does not contain active medication, it cannot address symptoms of stuttering but helps measure whether observed effects are due to actual drug action.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 65Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Native speakers of American English
Adults aged 18 to 65 years
Presence of stuttering confirmed with onset before age 6 years
Normal hearing
Healthy adults without hearing or language difficulties
You will not qualify if you...
Self-reported speech, language, or hearing difficulties other than stuttering
Self-reported neurological or psychological problems
Use of medications affecting the dopaminergic system or benzodiazepines
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - Single day dosing with assessments 3 to 4 hours after dose
Participants receive a single oral dose of either 10 mg aripiprazole or placebo in a randomized crossover design with triple masking.
1 dosing visit with post-dose assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Evaluating Aripiprazole and Sensorimotor Speech Processing in Adults Who Stutter
Evaluating the Blank Center CARE Model for Treating Stuttering in Children and Adults
A Telehealth and Speech-Language Pathology Approach for Fluency Disorders
Evaluation of Lumateperone Tablets for Adults with Moderate to Severe Childhood-Onset Stuttering
Double-Blind, Placebo-Controlled Phase 2 Trial
Study of Brain Activity in Adults Who Stutter During Speech Using MRI
Personalized Transcranial Alternating Current Stimulation tACS to Improve Brain Synchrony and Speech Fluency in Adults Who Stutter
Pilot Study of Transcranial Magnetic Stimulation to Reduce Stuttering in Adults Aged 18 to 65
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Study.